These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1482768)

  • 1. Elevated NMDA receptors in parkinsonian striatum.
    Weihmuller FB; Ulas J; Nguyen L; Cotman CW; Marshall JF
    Neuroreport; 1992 Nov; 3(11):977-80. PubMed ID: 1482768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
    Ułas J; Weihmuller FB; Brunner LC; Joyce JN; Marshall JF; Cotman CW
    J Neurosci; 1994 Nov; 14(11 Pt 1):6317-24. PubMed ID: 7965038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
    Chinaglia G; Alvarez FJ; Probst A; Palacios JM
    Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine.
    Eisch AJ; O'Dell SJ; Marshall JF
    Synapse; 1996 Mar; 22(3):217-25. PubMed ID: 9132989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice.
    Mash DC; Pablo J; Buck BE; Sanchez-Ramos J; Weiner WJ
    Exp Neurol; 1991 Oct; 114(1):73-81. PubMed ID: 1915737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
    Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
    Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.
    Niznik HB; Fogel EF; Fassos FF; Seeman P
    J Neurochem; 1991 Jan; 56(1):192-8. PubMed ID: 1987318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors.
    Tarazi FI; Campbell A; Yeghiayan SK; Baldessarini RJ
    Synapse; 1998 Oct; 30(2):227-35. PubMed ID: 9723793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medial dorsal striatum is more sensitive than lateral dorsal striatum to cocaine inhibition of exogenous dopamine clearance: relation to [3H]mazindol binding, but not striosome/matrix.
    Cline EJ; Adams CE; Larson GA; Gerhardt GA; Zahniser NR
    Exp Neurol; 1995 Jul; 134(1):135-49. PubMed ID: 7672034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration.
    González AM; Berciano J; Figols J; Pazos A; Pascual J
    Brain Res; 2000 Jan; 852(1):228-32. PubMed ID: 10661519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
    Calon F; Rajput AH; Hornykiewicz O; Bédard PJ; Di Paolo T
    Neurobiol Dis; 2003 Dec; 14(3):404-16. PubMed ID: 14678757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic innervation of the human striatum in Parkinson's disease.
    Porritt M; Stanic D; Finkelstein D; Batchelor P; Lockhart S; Hughes A; Kalnins R; Howells D
    Mov Disord; 2005 Jul; 20(7):810-8. PubMed ID: 15726582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.
    McCallum SE; Parameswaran N; Bordia T; McIntosh JM; Grady SR; Quik M
    Mol Pharmacol; 2005 Sep; 68(3):737-46. PubMed ID: 15933214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [3H]CNQX and NMDA-sensitive [3H]glutamate binding sites and AMPA receptor subunit RNA transcripts in the striatum of normal and weaver mutant mice and effects of ventral mesencephalic grafts.
    Mitsacos A; Tomiyama M; Stasi K; Giompres P; Kouvelas ED; Cortés R; Palacios JM; Mengod G; Triarhou LC
    Cell Transplant; 1999; 8(1):11-23. PubMed ID: 10338272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 99mTc-TRODAT-1 imaging of multiple system atrophy.
    Lu CS; Weng YH; Chen MC; Chen RS; Tzen KY; Wey SP; Ting G; Chang HC; Yen TC
    J Nucl Med; 2004 Jan; 45(1):49-55. PubMed ID: 14734673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography of striatal serotonin transporters in Parkinson disease.
    Kerenyi L; Ricaurte GA; Schretlen DJ; McCann U; Varga J; Mathews WB; Ravert HT; Dannals RF; Hilton J; Wong DF; Szabo Z
    Arch Neurol; 2003 Sep; 60(9):1223-9. PubMed ID: 12975287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.